The estimated Net Worth of Farah Champsi is at least $32 Million dollars as of 27 April 2017. Farah Champsi owns over 19,168 units of Trevena Inc stock worth over $37,165 and over the last 12 years Farah sold TRVN stock worth over $31,952,450.
Farah has made over 6 trades of the Trevena Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Farah sold 20,450 units of TRVN stock worth $1,836,206 on 14 June 2017.
The largest trade Farah's ever made was selling 447,499 units of Trevena Inc stock on 23 October 2013 worth over $6,940,709. On average, Farah trades about 57,450 units every 102 days since 2013. As of 27 April 2017 Farah still owns at least 4,962 units of Trevena Inc stock.
You can see the complete history of Farah Champsi stock trades at the bottom of the page.
Farah's mailing address filed with the SEC is 2225 Colorado Ave, Santa Monica, CA 90404, USA.
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, and Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Trevena Inc executives and other stock owners filed with the SEC include: